

**Electronic Supplementary Information**

**Straightforward one-pot synthesis of bioactive *N*-aryl oxazolidin-2-ones *via* highly efficient  $\text{Fe}_3\text{O}_4@\text{SiO}_2$ -supported acetate-based butylimidazolium ionic liquid nanocatalyst under metal- and solvent-free conditions**

Radhika Gupta, Manavi Yadav, Rashmi Gaur, Gunjan Arora and Rakesh Kumar Sharma\*

*Green Chemistry Network Centre, Department of Chemistry, University of Delhi, Delhi- 110007, India*


*[rksharmagreenchem@hotmail.com](mailto:rksharmagreenchem@hotmail.com)*

**Table of contents**


1. <b>Table S1</b> Calculation of crystallite size of IL-OAc@FSMNP catalyst from XRD data.	S2
2. <b>Fig. S1</b> Size distribution diagrams of (a) MNP, (b) SMNP, and (c) IL-OAc@FSMNP.	S2
3. <b>Fig. S2</b> SEM-coupled EDX spectrum of IL-OAc@FSMNP.	S3
4. <b>Fig. S3</b> (a) FT-IR spectra, and (b) magnetization curves of (i) fresh IL-OAc@FSMNP and (ii) recovered IL-OAc@FSMNP, (c) FE-SEM, and (d) TEM images of recovered IL-OAc@FSMNP.	S3
5. GC-MS spectra	S4
6. NMR and FT-IR data	S14
7. References	S18

**Table S1** Calculation of crystallite size of IL-OAc@FSMNP catalyst from XRD data.


Entry	2θ/degree	FWHM/degree	Size/nm
1	30.23	0.483	17.04
2	35.59	0.400	20.88
3	53.68	0.438	20.33
4	56.80	0.402	22.52
5	62.81	0.515	18.09



**Fig. S1** Size distribution diagrams of (a) MNP, (b) SMNP, and (c) IL-OAc@FSMNP.





**Fig. S2** SEM-coupled EDX spectrum of IL-OAc@FSMNP.





**Fig. S3** (a) FT-IR spectra, and (b) magnetization curves of (i) fresh IL-OAc@FSMNP and (ii) recovered IL-OAc@FSMNP, (c) FE-SEM, and (d) TEM images of recovered IL-OAc@FSMNP.


### GC-MS Spectra




























### NMR and FT-IR Data

**N-2, 4-dichlorophenoxyazolidin-2-one (Table 1, entry 6)**


$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , TMS)  $\delta$  7.43 (d,  $J = 2.3$  Hz, 1H), 7.32-7.24 (m, 2H), 4.47 (q,  $J = 7.3$  Hz, 2H), 3.94 (dd,  $J = 8.2, 7.3$  Hz, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , TMS)  $\delta$  156.6, 134.3, 133.5, 132.9, 130.2, 130.0, 128.1, 62.6, 46.8; IR ( $\text{cm}^{-1}$ ): 3095, 2923, 1747, 1476; M. Pt.: 110-113 °C






*N*-2,5-dichlorophenylloxazolidin-2-one (Table 1, entry 8)

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , TMS)  $\delta$  7.42-7.37 (m, 2H), 7.27-7.24 (dt,  $J = 8.7, 1.4$  Hz, 1H), 4.52 (td,  $J = 7.9, 1.2$  Hz, 2H), 4.01-3.98 (m, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , TMS)  $\delta$  156.5, 135.8, 133.2, 131.4, 130.6, 129.5, 129.4, 62.6, 46.8; IR ( $\text{cm}^{-1}$ ): 3093, 3073, 2921, 1726, 1478; M. Pt.: 110-113 °C





***N*-Phenylloxazolidin-2-one** (Table 1, entry 1)<sup>1-3</sup>

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS) δ 7.53-7.55 (m, 2H), 7.36-7.39 (m, 2H), 7.14-7.15 (m, 1H), 4.44-4.49 (m, 2H), 4.01-4.07 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS) δ 155.4, 138.4, 129.2, 124.2, 118.4, 61.4, 45.3; IR (cm<sup>-1</sup>): 3070, 3009, 2918, 1738; M. Pt.: 118-119 °C

**N-4-chlorophenyloxazolidin-2-one** (Table 1, entry 2)<sup>1, 4, 5</sup>

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS) δ 7.47-7.49 (m, 2H), 7.31-7.34 (m, 2H), 4.46-4.50 (m, 2H), 4.00-4.04 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS) δ 155.2, 137.0, 129.4, 129.2, 119.5, 61.4, 45.2; IR (cm<sup>-1</sup>): 1740. M. Pt.: 118.5-119 °C

**N-4-bromophenyloxazolidin-2-one** (Table 1, entry 3)<sup>1, 2, 6</sup>

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS) δ 7.41-7.48 (m, 4H), 4.45-4.49 (m, 2H), 3.99-4.03 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS) δ 155.1, 137.5, 132.1, 119.8, 117.0, 61.4, 45.1; IR (cm<sup>-1</sup>) 3123, 3071, 3012, 2984, 2953, 2923, 1739, 1590; M. Pt.: 132-133 °C

**N-4-methylphenyloxazolidin-2-one** (Table 1, entry 4)<sup>2, 5, 7, 8</sup>

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS) δ 7.42 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 4.48 (t, J = 8.0 Hz, 2H), 4.04 (t, J = 8.0 Hz, 2H), 2.33 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 155.6, 143.2, 135.9, 134.0, 129.8, 129.0, 118.6, 61.5, 45.6, 21.0. IR (cm<sup>-1</sup>): 3034, 2925, 1728, 1515; M. Pt.: 91 °C

**N-4-methoxyphenyloxazolidin-2-one** (Table 1, entry 5)<sup>1, 2, 9</sup>

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS) δ 7.43 (d, J = 9.2 Hz, 2H), 6.91 (d, J = 9.2 Hz, 2H), 4.46 (t, J = 8.0 Hz, 2H), 4.01 (t, J = 8.0 Hz, 2H), 3.78 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS) δ 156.5, 155.7, 131.6, 120.4, 114.4, 61.4, 55.6, 45.8; IR (cm<sup>-1</sup>): 2981, 2972, 2890, 2839, 1723, 1513; M. Pt.: 112-114 °C

**N-3,5-dichlorophenyloxazolidin-2-one** (Table 1, entry 9)<sup>7</sup>

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, TMS) δ 7.52 (s, 2H), 7.15 (s, 1H), 4.53 (t, J = 8.0 Hz, 2H), 4.05 (t, J = 8.0 Hz, 2H).

**N-2-nitrophenyloxazolidin-2-one** (Table 1, entry 11)<sup>10, 11</sup>

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS): δ 4.10 (t, J = 7.8 Hz, 2H), 4.59 (t, J = 7.8 Hz, 2H), 7.44-7.49 (m, 2H), 7.67 (dd, J = 7.8, 7.8 Hz, 1H), 7.67 (d, J = 8.2 Hz, 1H); <sup>13</sup>C NMR (60 MHz, CDCl<sub>3</sub>, TMS): δ 47.4, 62.8, 126.0, 128.0, 128.1, 131.6, 133.9, 145.6, 156.2; M. Pt.: 165 °C

**N-4-nitrophenyloxazolidin-2-one** (Table 1, entry 13)<sup>3</sup>

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, TMS) δ 8.25 (d, J = 9.2 Hz, 2H), 7.72 (d, J = 9.6 Hz, 2H), 4.54 (t, J = 8.0 Hz, 2H), 4.12 (t, J = 8.0 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, TMS) δ 143.9, 126.6, 125.2, 117.6, 111.4, 61.6, 45.1; IR (cm<sup>-1</sup>) 3445, 2925, 2853, 1761, 1596, 1514, 1480; M. Pt.: 153-156 °C

**N-4-acetylphenyloxazolidin-2-one** (Table 1, entry 14)<sup>2, 9</sup>

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.03-7.88 (m, 2H), 7.70-7.57 (m, 2H), 4.52 (dd, J = 8.9, 7.0 Hz, 2H), 4.10 (dd, J = 8.9, 7.0 Hz, 2H), 2.58 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 197.4, 155.4, 142.9, 133.1, 130.2, 117.8, 61.9, 45.4, 27.0; IR (cm<sup>-1</sup>): 2972, 2913, 1745, 1735, 1665; M. Pt.: 146-147 °C

**References:**

1. E. H. Elageed, B. Wang, Y. Zhang, S. Wu and G. Gao, *J. Mol. Catal. A: Chem.*, 2015, **408**, 271-277.
2. W. Mahy, P. K. Plucinski and C. G. Frost, *Org. Lett.*, 2014, **16**, 5020-5023.
3. S. Jammie, S. Sakthivel, L. Rout, T. Mukherjee, S. Mandal, R. Mitra, P. Saha and T. Punniyamurthy, *J. Org. Chem.*, 2009, **74**, 1971-1976.
4. A. Baba, H. Kishiki, I. Shibata and H. Matsuda, *Organometallics*, 1985, **4**, 1329-1333.
5. R. Adams and J. Segur, *J. Am. Chem. Soc.*, 1923, **45**, 785-790.
6. S. Cacchi, G. Fabrizi and A. Goggiamani, *Heterocycles*, 2003, **61**, 505-512.
7. B. Wang, E. H. Elageed, D. Zhang, S. Yang, S. Wu, G. Zhang and G. Gao, *ChemCatChem*, 2014, **6**, 278-283.
8. G. C. Chiang and T. Olsson, *Org. Lett.*, 2004, **6**, 3079-3082.
9. B. Mallesham, B. Rajesh, P. R. Reddy, D. Srinivas and S. Trehan, *Org. Lett.*, 2003, **5**, 963-965.
10. H. Gong and N.-f. Yang, *Heterocycles*, 2009, **78**, 2093-2100.
11. R. Oda, M. Miyanoki and M. Okano, *Bull. Chem. Soc. Jpn.*, 1962, **35**, 1309-1312.